Dashboard Systems: Implementing Pharmacometrics from Bench to Bedside
Journal Title: The AAPS Journal - Year 2014, Vol 16, Issue 5
Abstract
In recent years, there has been increasing interest in the development of medical decision-support tools, including dashboard systems. Dashboard systems are software packages that integrate information and calculations about therapeutics from multiple components into a single interface for use in the clinical environment. Given the high cost of medical care, and the increasing need to demonstrate positive clinical outcomes for reimbursement, dashboard systems may become an important tool for improving patient outcome, improving clinical efficiency and containing healthcare costs. Similarly the costs associated with drug development are also rising. The use of model-based drug development (MBDD) has been proposed as a tool to streamline this process, facilitating the selection of appropriate doses and making informed go/no-go decisions. However, complete implementation of MBDD has not always been successful owing to a variety of factors, including the resources required to provide timely modeling and simulation updates. The application of dashboard systems in drug development reduces the resource requirement and may expedite updating models as new data are collected, allowing modeling results to be available in a timely fashion. In this paper, we present some background information on dashboard systems and propose the use of these systems both in the clinic and during drug development.
Authors and Affiliations
Diane R. Mould, Richard N. Upton, Jessica Wojciechowski
Keywords
Related Articles
- EP ID EP681661
- DOI 10.1208/s12248-014-9632-5
- Views 79
- Downloads 0
Sequential Bioequivalence Approaches for Parallel Designs
The online version of this article (doi:10.1208/s12248-014-9571-1) contains supplementary material, which is available to authorized users.
Common Deficiencies with Bioequivalence Submissions in Abbreviated New Drug Applications Assessed by FDA
A generic product must meet the standards established by the Food and Drug Administration (FDA) to be approved for marketing in the USA. FDA approves a generic product for marketing if it is proved to be therapeutically...
International Veterinary Bioequivalence Guideline Similarities and Differences Between Australia, Canada, Europe, Japan, New Zealand and the United States
Considering the diversity in physiology between species and the numerous dosage forms that exist in veterinary drug products, there are numerous complex issues that arise from the development and regulation of veterinary...
Phosphorothioate Oligonucleotide Quantification by μ-Liquid Chromatography-Mass Spectrometry
Phosporothioate oligonucleotides represent an important class of therapeutic oligonucleotides, in which none-bridging oxygen atoms of the phosphate groups are replaced by sulfur. These oligonucleotides are designed to tr...
Specificity and Accuracy Data for Ligand-binding Assays for Macromolecules Should be Interpreted with Caution